Centene (NYSE:CNC) Posts Earnings Results, Beats Estimates By $0.48 EPS

Centene (NYSE:CNC) posted its quarterly earnings data on Tuesday. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.48, FiscalAI reports. Centene had a positive return on equity of 12.12% and a negative net margin of 2.51%. The business had revenue of $50.65 billion during the quarter, compared to analysts’ expectations of $47.12 billion. During the same quarter in the previous year, the firm earned $0.50 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year.

Here are the key takeaways from Centene’s conference call:

• Centene raised its 2026 adjusted EPS outlook to above $5.20, up from above $4.80, after third-quarter adjusted EPS of $0.58 exceeded expectations. The increase reflects stronger Medicare results, improved Marketplace profitability, and lower interest expense.
• Medicare performance outpaced expectations, with Medicare Advantage on track to reach breakeven in 2026—one year ahead of plan—while Part D margins are now expected in the mid-to-high 3% range and enrollment is positioned for growth.
• Marketplace results continued to improve, with the company targeting a full-year pre-tax margin near 5% versus a loss in 2025. Centene said moderating utilization in higher-acuity silver plans and stronger underlying performance offset higher reserves for dispute-resolution and other program-integrity matters.
• Medicaid remained broadly on plan, with a third-quarter HBR of 93.6% and full-year membership expected to decline 8%–9% from year-end 2025. Management cited early signs of stabilization in behavioral and home-health trends, but work requirements and eligibility changes remain important execution risks for 2027.
• Centene repurchased $1.1 billion of senior notes, reducing total debt to $15.0 billion from $18.5 billion at the end of 2024, while continued cost-optimization efforts are expected to lower the consolidated SG&A rate in 2027. Management also expects 2027 adjusted EPS to grow from both the revised 2026 outlook and its estimated $4.70 underlying earnings base.

Centene Price Performance

Shares of CNC stock opened at $67.11 on Thursday. The stock has a 50 day moving average of $65.94 and a two-hundred day moving average of $55.04. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 0.71. Centene has a 12 month low of $31.63 and a 12 month high of $72.50. The company has a market capitalization of $33.15 billion, a P/E ratio of -6.43, a P/E/G ratio of 0.44 and a beta of 1.13.

Insider Buying and Selling at Centene

In other news, General Counsel Christopher Koster sold 56,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $66.90, for a total transaction of $3,779,850.00. Following the sale, the general counsel directly owned 248,854 shares in the company, valued at approximately $16,648,332.60. The trade was a 18.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.37% of the company’s stock.

Key Headlines Impacting Centene

Here are the key news stories impacting Centene this week:

• Positive Sentiment: Q3 earnings beat expectations. Centene reported adjusted EPS of $0.58, versus the $0.10 analyst consensus, while revenue reached $50.65 billion, ahead of the $47.12 billion estimate. Revenue increased 1.9% year over year. Centene Stock Approaches 52-Week High on Faster-Than-Expected Earnings Recovery
• Positive Sentiment: Management raised its 2026 outlook. Centene now expects adjusted EPS above $5.20, with the Medicare business reaching breakeven roughly a year earlier than planned. Medicare revenue growth and signs of a faster recovery were key drivers of the upgrade. Centene Forecasts 2026 Adjusted EPS Greater Than $5.20
• Positive Sentiment: Analysts raised price targets. Barclays lifted its target to $82 and retained an overweight rating, while Cantor Fitzgerald raised its target to $79. UBS increased its target to $78 but maintained a neutral rating, indicating analysts see upside while remaining cautious. Centene Analysts Boost Their Forecasts Following Upbeat Q3 Earnings
• Neutral Sentiment: Value investors view CNC favorably. Recent commentary highlights Centene’s long-term value potential and improving earnings estimates, although the stock’s rapid recovery has raised questions about whether much of the optimism is already reflected in the valuation. Centene Earnings Beat Raises Valuation Question
• Negative Sentiment: Membership pressures remain a concern. Medicaid enrollment has declined, and management continues to face risks from Medicaid margins and membership trends. These issues could limit the benefit of Medicare’s recovery and help explain the stock’s pullback after the earnings announcement. Centene Q3 Earnings Lift Guidance as Membership Pressures Linger
• Negative Sentiment: Options activity signals caution. High-volume put-option buying indicates that some traders are positioning for additional downside or seeking protection after the recent rally. Stock Traders Buy High Volume of Put Options on Centene

Analysts Set New Price Targets

CNC has been the topic of several recent analyst reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $69.00 price target on shares of Centene in a research report on Thursday. Stifel Nicolaus set a $79.00 price objective on Centene in a research report on Monday, August 3rd. Wells Fargo & Company set a $69.00 target price on shares of Centene and gave the stock an “equal weight” rating in a research report on Monday, July 13th. Argus raised shares of Centene from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research report on Tuesday, August 11th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $79.00 target price (up from $68.00) on shares of Centene in a research note on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Centene presently has a consensus rating of “Hold” and a consensus target price of $72.90.

About Centene

Centene Corporation is a diversified healthcare enterprise that provides government-sponsored and commercial health insurance programs and related healthcare services. The company’s offerings are primarily focused on Medicaid, Medicare, and health insurance marketplace plans, with an emphasis on serving individuals and families who may have limited access to traditional healthcare coverage.

Centene operates Medicaid health plans through state-based contracts and offers Medicare Advantage, Medicare prescription drug, and Medicare Supplement products through its Wellcare brand.